Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRISVILLE, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (Liquidia ...
An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing ...
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...
An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson's disease medication delivered through an infusion pump is safe and effective at reducing ...
The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...
Study design: Retrospective single centre study. Objectives: To evaluate a low-dose radioisotope imaging procedure for assessment of implanted intrathecal drug delivery and to compare the radiation ...
AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous ...
Zacks Investment Research on MSN
KRMD submits 510(k) to use FreedomEDGE system with oncology biologic
KORU Medical Systems, Inc.KRMD recently announced that it has submitted a 510(k) premarket notification for FDA clearance to ...
Around 1,000 people with Parkinson’s disease will be able to access treatment with AbbVie’s Produodopa, the first therapy that can be delivered by a 24-hour ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback